Skip to content

menu

Pharma in Brief logo
HomeAboutContact
Search
Close
Pharmaceuticals and life sciencesIntellectual propertyLife sciences and healthcare
View topics Archives
Subscribe

Pharma in Brief

Ontario Drug Benefit Act

Subscribe to Ontario Drug Benefit Act via RSS

Ontario proposes removing barrier to listing “well-established drugs” on its public formulary

Photo of Julia WonPhoto of Paul JorgensenPhoto of Kristin Wall
By Julia Won, Paul Jorgensen & Kristin Wall on November 5, 2023

On October 19, 2023, the Ontario government proposed regulatory amendments that may eliminate the need to submit certain clinical studies and evidence when requesting that a “well-established drug” be (i) listed or (ii) designated as interchangeable on Ontario’s publicly-funded formulary. …

Ontario reduces restrictions on ordinary commercial term benefits and private label products

Photo of Randy SuttonPhoto of William Chalmers
By Randy Sutton & William Chalmers on December 17, 2019

The Ontario Ministry of Health and Long-Term Care (the Ministry) introduced changes to regulations (collectively, the Regulations) made under the Ontario Drug Benefit Act (ODBA) and the Drug Interchangeability and Dispensing Fee Act (DIDFA).…

Subscribe to Pharma in Brief

Subscribe to this publication

Ontario consults on changes to streamline drug formulary listing and reduce government payments to pharmacies

Photo of Kristin WallPhoto of William Chalmers
By Kristin Wall & William Chalmers on November 10, 2019

The Ontario Ministry of Health and Long-Term Care (the Ministry) has proposed draft amendments to Regulations made under the Ontario Drug Benefit Act (ODBA) and the Ontario Drug Interchangeability and Dispensing Fee Act. The proposed changes…

Pharma in Brief

LinkedIn Twitter Facebook RSS YouTube
Published by
Norton Rose Fulbright LLP logo
DisclaimerPrivacy policy

About

Stay up-to-date with legal and regulatory developments affecting the pharmaceutical industry. Pharma in Brief provides timely updates with a focus on the key take-away you need to know.

Read more

Topics

Archives

Copyright © 2025, Norton Rose Fulbright LLP. All rights reserved.